The results of phase 3 prove that Pfizer and Eli Lilly have come a step closer to get tanzeumab - an antibody blocking the nerve growth factor (NGF) and an alternative to opioids applied to treat chronic pain - at the filing stage of trials.
While the partners informed the public of their research results back in the summer, they have not disclosed any details until now.The antibody discovered proves successful in the treatment of patients affected by osteoarthritis of the knee and hip that strive for relieving themselves from pain by means of opioids or nonsteroidal anti-inflammatory drugs.
Further stages of research are expected to be announced in the first half of 2019.They are to concern chronic lower back pain and cancer-related pain.Pfizer and Lilly need to hurry if they want to sustain the market attractiveness of tanezumab, though. The reason is that its competitive therapy - a blocker named fasinumab - is also being subject to studies now. If the companies manage to succeed, they can count on drawing profit from a multi-billion market for analgesics that provide powerful pain alleviation - particularly in the context of the present addiction epidemic.